Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Mutation Analysis in 200 Cases of Newly Diagnosed Myelodysplastic Syndrome By Next Generation Sequencing: Association with Established Prognostic Variables and IPSS-R

Kankana Ghosh, B. Pharm, Parsa Hodjat, MD, Priyanka Priyanka, MPH, Beenu Thakral, MBBS,MD, Keyur P. Patel, MD PhD, Mark Routbort, MD PhD, Rashmi Kanagal-Shamana, MD, C. Cameron Yin, MDPhD, Zhuang Zuo, MD PhD, Raja Luthra, PhD, Tariq Muzzafar, MD

Blood (2015) 126 (23): 1703.

https://doi.org/10.1182/blood.V126.23.1703.1703

Published: 2015

Journal Articles

Mutation Analysis in 276 Cases of Newly Diagnosed Acute Myeloid Leukemia By Next Generation Sequencing: Association with Established Prognostic Variables and MRC Risk Groups

Parsa Hodjat, MD, Kankana Ghosh, B. Pharm, Priyanka Priyanka, MPH, Beenu Thakral, MBBS,MD, Keyur P. Patel, MD PhD, Mark Routbort, MD PhD, Rashmi Kanagal-Shamana, MD, C. Cameron Yin, MDPhD, Zhuang Zuo, MD PhD, Raja Luthra, PhD, Tariq Muzzafar, MD

Blood (2015) 126 (23): 1392.

https://doi.org/10.1182/blood.V126.23.1392.1392

Published: 2015

Journal Articles

Gene Expression Profiling for Molecular Features of Response in a Phase I Trial of Alisertib Plus Romidepsin for Relapsed/Refractory Aggressive B- and T-Cell Lymphomas

Blood (2015) 126 (23): 2705.

https://doi.org/10.1182/blood.V126.23.2705.2705

Published: 2015

Journal Articles

Validation of Alternative Chronic Myelomonocytic Leukemia (CMML)-Specific Prognostic Scoring (CPSS) System in UT MD Anderson Cancer Center Cohort

Priyanka Priyanka, BAMS, Janhavi Raut, BDS, Patricia S Fox, MS, Francesco Stingo, PhD, Tariq Muzzafar, MD

Blood (2014) 124 (21): 3278.

https://doi.org/10.1182/blood.V124.21.3278.3278

Published: 2014

Journal Articles

A Phase I Trial of Alisertib Plus Romidepsin for Relapsed/Refractory Aggressive B- and T-Cell Lymphomas

Michelle A. Fanale, MD, Fredrick B. Hagemeister, MD, Luis Fayad, MD, Yasuhiro Oki, MD, Nathan Fowler, MD, Jorge Romaguera, MD, Nina Shah, Hubert Chuang, MD, Lei Feng, MS, Sandra B Horowitz, PharmD, Emily Wesson, APN, Toni Y Hutto, BS, Tariq Muzzafar, MD, Felipe Samaniego, MD, R Eric Davis, MD

Blood (2014) 124 (21): 1744.

https://doi.org/10.1182/blood.V124.21.1744.1744

Published: 2014

NARROW

Mutation Analysis in 200 Cases of Newly Diagnosed Myelodysplastic Syndrome By Next Generation Sequencing: Association with Established Prognostic Variables and IPSS-R

Mutation Analysis in 276 Cases of Newly Diagnosed Acute Myeloid Leukemia By Next Generation Sequencing: Association with Established Prognostic Variables and MRC Risk Groups

Gene Expression Profiling for Molecular Features of Response in a Phase I Trial of Alisertib Plus Romidepsin for Relapsed/Refractory Aggressive B- and T-Cell Lymphomas

Validation of Alternative Chronic Myelomonocytic Leukemia (CMML)-Specific Prognostic Scoring (CPSS) System in UT MD Anderson Cancer Center Cohort

A Phase I Trial of Alisertib Plus Romidepsin for Relapsed/Refractory Aggressive B- and T-Cell Lymphomas

Email alerts

ASH Publications

American Society of Hematology

Mutation Analysis in 200 Cases of Newly Diagnosed Myelodysplastic Syndrome By Next Generation Sequencing: Association with Established Prognostic Variables and IPSS-R

Mutation Analysis in 276 Cases of Newly Diagnosed Acute Myeloid Leukemia By Next Generation Sequencing: Association with Established Prognostic Variables and MRC Risk Groups

Gene Expression Profiling for Molecular Features of Response in a Phase I Trial of Alisertib Plus Romidepsin for Relapsed/Refractory Aggressive B- and T-Cell Lymphomas

Validation of Alternative Chronic Myelomonocytic Leukemia (CMML)-Specific Prognostic Scoring (CPSS) System in UT MD Anderson Cancer Center Cohort

A Phase I Trial of Alisertib Plus Romidepsin for Relapsed/Refractory Aggressive B- and T-Cell Lymphomas

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only